Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy

Radiochemotherapy is leading the universal research effort in fighting lethality: it is improving relapse-free survival of patients with inoperable glioblastoma, the most pernicious brain tumor in adults. Its effectiveness was found to depend on expression of Mgmt gene of tumor DNA reparation follow...

Full description

Saved in:
Bibliographic Details
Published inVoprosy onkologij Vol. 57; no. 2; p. 245
Main Authors Matsko, M V, Luchin, E I, Ievleva, A G, Bakholdin, D V, Abysheva, S N, Zavgorodniaia, E V, Potapova, O N, Imianitov, E N, Ulitin, A Iu, Matsko, D E
Format Journal Article
LanguageRussian
Published Russia (Federation) 2011
Subjects
Adult
Antineoplastic Agents, Alkylating - therapeutic use
Biomarkers, Tumor - metabolism
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
Brain Neoplasms - radiotherapy
Chemotherapy, Adjuvant
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
DNA Modification Methylases - metabolism
DNA Repair Enzymes - metabolism
DNA, Neoplasm - drug effects
DNA, Neoplasm - radiation effects
Dose Fractionation
Gene Expression Regulation, Neoplastic
Glioblastoma - metabolism
Glioblastoma - pathology
Glioblastoma - radiotherapy
Humans
Magnetic Resonance Imaging
Male
Protons - therapeutic use
Radiotherapy, Adjuvant
Radiotherapy, Conformal - methods
Treatment Outcome
Tumor Suppressor Proteins - metabolism
Online AccessGet more information

Cover

More Information
Summary:Radiochemotherapy is leading the universal research effort in fighting lethality: it is improving relapse-free survival of patients with inoperable glioblastoma, the most pernicious brain tumor in adults. Its effectiveness was found to depend on expression of Mgmt gene of tumor DNA reparation following radiochemotherapy and adequate medication based on the molecular phenotype of tumor. Our study involved a 40-year old male with a low level of Mgmt gene expression as established by stereotactic biopsy. The patient received hypofractionated three-dimensional conformational proton therapy with the benefit of temozolomide (140 mg/24 hr). Subsequently, the dose was raised to 360 mg/24 hr, on days 1-5 of the cycle. Contrast-enhanced MRI examination established significant diminishing of the size of tumors on completion of cycles 7 and 8; patients felt better, memory and blood indices improved. As of the time this paper was written, relapse-free survival was 17.5 months, as compared with the literature data on inoperable glioblastoma--5.5 months.
ISSN:0507-3758